Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest CancerVax Stories

2009-04-22 06:00:00

Study Presented at 2009 AACR Meeting Highlights Potential Therapeutic Approach to Treat Patients Unresponsive to Erbitux and Vectibix DENVER, April 22 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, yesterday presented non-clinical data at the annual meeting of the American Association for Cancer Research (AACR). These non-clinical data indicate...

2009-04-22 06:00:00

DENVER, April 22 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, yesterday presented data at the annual meeting of the American Association for Cancer Research (AACR) in Denver, Colorado, showing that its BiTE(R) antibody MT110 can eliminate cancer stem cells (1). Cancer stem cells are thought to be responsible for resistance of human cancers to...

2009-04-15 06:00:00

BETHESDA, Md., April 15 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it will host an investor meeting and will ring the closing bell of the NASDAQ stock exchange in New York City on Friday, April 24, 2009. A simultaneous webcast of the investor meeting will be available on the company's website at www.micromet-inc.com....

2009-04-08 06:00:00

BETHESDA, Md., April 8 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the publication of data in the peer-reviewed Journal of Immunotherapy (1) demonstrating the potent anti-tumor activity of a BiTE antibody binding to carcinoembryonic antigen (CEA) and to CD3 on T cells. Micromet and MedImmune are jointly developing MT111/MEDI-565,...

2009-04-02 06:00:00

BETHESDA, Md., April 2 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the filing of the first clinical trial application (CTA) in Europe by its partner Nycomed for the anti-GM-CSF antibody MT203. Micromet received a payment of 1.5 million Euro (US$ 2.0 million) from Nycomed for the achievement of this milestone. Under a 2007...

2009-03-26 06:00:00

BETHESDA, Md., March 26 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that its President and CEO, Dr. Christian Itin, will present at the Future Leaders in the Biotech Industry conference at the Millennium Broadway Hotel & Conference Center in New York City on Thursday, April 2, 2009. A simultaneous webcast of the presentation...

2009-03-23 06:00:00

Randomized, Controlled, Multicenter Trial Will Test Ability of Adecatumumab to Prolong Disease Free Survival in High Risk Patients with Liver Metastases BETHESDA, Md., March 23 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the commencement of a randomized, controlled phase 2 trial of its human anti-EpCAM IgG1 antibody adecatumumab...

2009-03-19 06:00:00

Appointments Strengthen Expertise in Immunotherapy of Cancer BETHESDA, Md., March 19 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the the appointment of Sir Walter Bodmer and Bernard Fox to its BiTE antibody advisory panel. Other members of the company's advisory panel include professors Richard Flavell (Yale University), Michael...

2009-03-16 06:00:00

BETHESDA, Md., March 16 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the publication of six abstracts for poster presentations at the 100th annual meeting of AACR taking place from April 20-24, 2009, in Denver, Colorado. The following posters will be presented: Lutterbuese, R. et al. (2009). Highly efficient lysis of KRAS- and...

2009-03-12 06:00:00

BETHESDA, Md., March 12 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it is regaining from its partner MedImmune the rights in North America to its most advanced BiTE antibody candidate, blinatumomab, also known as MT103. In Europe, Micromet is conducting a phase 2 clinical trial with blinatumomab for the treatment of patients...